Tenderwize
Zurück zur Suche

Open-house rebate agreement for Aflibercept (excluding 114.3 mg/ml)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 432 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aflibercept, ausgenommen 114,3 mg/ml, ATC S01LA05

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The notice uses an open-house model while the form type is 'open'; although the buyer explains this, the procedural fra...

Paper submissions are only timely if the scan is sent in advance and the original paper documents arrive by the 10th of...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive rebate agreements for the medicinal product Aflibercept, excluding 114.3 mg/ml, ATC S01LA05.
  • Supply contract for pharmaceutical products under an open-house model.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Aflibercept (excluding 114.3 mg/ml, ATC S01LA05). It is not a competitive award procedure in the usual sense: the buyer states that any pharmaceutical company meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract period runs from 2026-01-01 to 2027-12-31, with contract entry possible until 2027-11-03. Submission is via DTVP electronic portal with qualified electronic signature or by signed paper originals in duplicate. No contract value is stated.

Risiken

The notice uses an open-house model while the form type is 'open'; although the buyer explains this, the procedural fra...

Paper submissions are only timely if the scan is sent in advance and the original paper documents arrive by the 10th of...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Aflibercept (excluding 114.3 mg/ml)

Open-house supply arrangement for pharmaceutical rebate agreements concerning Aflibercept, excluding 114.3 mg/ml, ATC S01LA05. The lot is described as a non-exclusive, identical, non-individually negotiable contract offered to all interested pharmaceutical companies meeting the suitability requirement. Source: structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Dec 2025 - Dec 2027

Kategorie

Pharmaceutical products

Frist

Deadline Nov 03, 2027

Vergabedetails

Veröffentlichungsdatum
16 Nov 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
760140-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30